Steve Elliott

Summary

Affiliation: Amgen Inc
Country: USA

Publications

  1. doi request reprint Erythropoiesis-stimulating agents
    Steve Elliott
    Department of Hematology, Amgen, Inc, Thousand Oaks, CA 91320, USA
    Cancer Treat Res 157:55-74. 2011
  2. pmc Epo receptors are not detectable in primary human tumor tissue samples
    Steve Elliott
    Amgen Inc, Thousand Oaks, California, United States of America
    PLoS ONE 8:e68083. 2013
  3. doi request reprint Abuse of medicines for performance enhancement in sport: why is this a problem for the pharmaceutical industry?
    Steve Elliott
    Department of Hematology, Amgen, Inc, One Amgen Center, Thousand Oaks, CA 91320, USA
    Bioanalysis 4:1681-90. 2012
  4. doi request reprint Identification of a sensitive anti-erythropoietin receptor monoclonal antibody allows detection of low levels of EpoR in cells
    Steve Elliott
    Amgen Inc, One Amgen Center, Thousand Oaks, CA 91320, United States
    J Immunol Methods 352:126-39. 2010
  5. doi request reprint Erythropoietins: a common mechanism of action
    Steve Elliott
    Amgen Inc, Thousand Oaks, CA 91320 1799, USA
    Exp Hematol 36:1573-84. 2008
  6. ncbi request reprint Anti-Epo receptor antibodies do not predict Epo receptor expression
    Steve Elliott
    Amgen Inc, One Amgen Center Dr, Thousand Oaks, CA 91320, USA
    Blood 107:1892-5. 2006
  7. ncbi request reprint Control of rHuEPO biological activity: the role of carbohydrate
    Steve Elliott
    Amgen Inc, Thousand Oaks, Calif 91320, USA
    Exp Hematol 32:1146-55. 2004
  8. ncbi request reprint Structural requirements for additional N-linked carbohydrate on recombinant human erythropoietin
    Steve Elliott
    Amgen, Thousand Oaks, California 91320, USA
    J Biol Chem 279:16854-62. 2004
  9. ncbi request reprint Enhancement of therapeutic protein in vivo activities through glycoengineering
    Steve Elliott
    Amgen, One Amgen Center, Thousand Oaks, CA 91320, USA
    Nat Biotechnol 21:414-21. 2003
  10. doi request reprint Lack of expression and function of erythropoietin receptors in the kidney
    Steve Elliott
    Hematology, Amgen Inc, Thousand Oaks, CA, USA
    Nephrol Dial Transplant 27:2733-45. 2012

Collaborators

Detail Information

Publications18

  1. doi request reprint Erythropoiesis-stimulating agents
    Steve Elliott
    Department of Hematology, Amgen, Inc, Thousand Oaks, CA 91320, USA
    Cancer Treat Res 157:55-74. 2011
    ..In this chapter, the control of Epo levels and erythropoiesis, the various forms of ESAs used commercially, and their physical and biological properties are discussed...
  2. pmc Epo receptors are not detectable in primary human tumor tissue samples
    Steve Elliott
    Amgen Inc, Thousand Oaks, California, United States of America
    PLoS ONE 8:e68083. 2013
    ..Taken together these results raise questions about the hypothesis that most tumors express high levels of functional EpoR protein. ..
  3. doi request reprint Abuse of medicines for performance enhancement in sport: why is this a problem for the pharmaceutical industry?
    Steve Elliott
    Department of Hematology, Amgen, Inc, One Amgen Center, Thousand Oaks, CA 91320, USA
    Bioanalysis 4:1681-90. 2012
    ..A strong, united front between the biopharmaceutical industry and anti-doping agencies is essential to counter the misuse of medicines for performance enhancement, as well as to promote fair play and clean sport...
  4. doi request reprint Identification of a sensitive anti-erythropoietin receptor monoclonal antibody allows detection of low levels of EpoR in cells
    Steve Elliott
    Amgen Inc, One Amgen Center, Thousand Oaks, CA 91320, United States
    J Immunol Methods 352:126-39. 2010
    ..These results indicate that A82 can be used to examine low level EpoR expression in cells by western and flow cytometry allowing an improved understanding of EpoR expression and metabolism...
  5. doi request reprint Erythropoietins: a common mechanism of action
    Steve Elliott
    Amgen Inc, Thousand Oaks, CA 91320 1799, USA
    Exp Hematol 36:1573-84. 2008
    ..PEGylation of EPO (addition of polyethylene glycol) has been used to further extend the terminal half-life. Also, new strategies are under investigation for stimulating erythropoiesis through activation of the EPO receptor...
  6. ncbi request reprint Anti-Epo receptor antibodies do not predict Epo receptor expression
    Steve Elliott
    Amgen Inc, One Amgen Center Dr, Thousand Oaks, CA 91320, USA
    Blood 107:1892-5. 2006
    ..We concluded that these antibodies have limited utility for detecting EpoR. Thus, reports of EpoR expression in tumor cells using these antibodies should be viewed with caution...
  7. ncbi request reprint Control of rHuEPO biological activity: the role of carbohydrate
    Steve Elliott
    Amgen Inc, Thousand Oaks, Calif 91320, USA
    Exp Hematol 32:1146-55. 2004
    ..Glycosylation analogs with altered N-linked carbohydrate content were compared with rHuEPO to elucidate the relationship between carbohydrate content and activity...
  8. ncbi request reprint Structural requirements for additional N-linked carbohydrate on recombinant human erythropoietin
    Steve Elliott
    Amgen, Thousand Oaks, California 91320, USA
    J Biol Chem 279:16854-62. 2004
    ..However, it was noted that recombinant human erythropoietin analogs that were hyperglycosylated at sites that were normally buried had altered protein structures. This suggests that carbohydrate addition precedes polypeptide folding...
  9. ncbi request reprint Enhancement of therapeutic protein in vivo activities through glycoengineering
    Steve Elliott
    Amgen, One Amgen Center, Thousand Oaks, CA 91320, USA
    Nat Biotechnol 21:414-21. 2003
    ..This strategy has been validated clinically for glycoengineered rHuEPO (darbopoetin alfa)...
  10. doi request reprint Lack of expression and function of erythropoietin receptors in the kidney
    Steve Elliott
    Hematology, Amgen Inc, Thousand Oaks, CA, USA
    Nephrol Dial Transplant 27:2733-45. 2012
    ..Recently positive and negative control cell types were validated and a sensitive and specific anti-EpoR antibody (A82) that detects low levels of EpoR protein was described...
  11. ncbi request reprint Glycoengineering: the effect of glycosylation on the properties of therapeutic proteins
    Angus M Sinclair
    Amgen, Inc, One Amgen Center Drive, Thousand Oaks, CA 91320 1799, USA
    J Pharm Sci 94:1626-35. 2005
    ..Carbohydrates on DA and other molecules can also increase molecular stability, solubility, increase in vivo biological activity, and reduce immunogenicity. These properties are discussed...
  12. doi request reprint Investigation of the effects of altered receptor binding activity on the clearance of erythropoiesis-stimulating proteins: Nonerythropoietin receptor-mediated pathways may play a major role
    Balaji Agoram
    Department of Pharmacokinetics and Drug Metabolism, Amgen Inc, One Amgen Center Drive, Thousand Oaks, California 91320 1799, USA
    J Pharm Sci 98:2198-211. 2009
    ....
  13. ncbi request reprint Expression and function of erythropoietin receptors in tumors: implications for the use of erythropoiesis-stimulating agents in cancer patients
    Angus M Sinclair
    Amgen Inc, Thousand Oaks, California, USA
    Cancer 110:477-88. 2007
    ..For this report, the authors reviewed the biology of EpoR in erythropoiesis and compared and contrasted the reported findings on the role of ESAs and EpoR in tumors...
  14. ncbi request reprint Kinetics of haematopoietic recovery after dose-intensive chemo/radiotherapy in mice: optimized erythroid support with darbepoetin alpha
    Cynthia Hartley
    Departments of Hematology Research and Pharmacokinetics, Amgen Inc, One Amgen Center Drive, Thousand Oaks, CA 91320, USA
    Br J Haematol 122:623-36. 2003
    ..There was no evidence that erythropoietic agents exacerbated anaemia, even when administered immediately prior to CRT in an attempt to "prime" erythroid cells for the effects of CRT...
  15. ncbi request reprint Drug-induced and antibody-mediated pure red cell aplasia: a review of literature and current knowledge
    Ralph Smalling
    Amgen Inc, One Amgen Center Drive, M S 24 1 C, Thousand Oaks, CA 91320 1799, USA
    Biotechnol Annu Rev 10:237-50. 2004
    ..A literature review was undertaken to document the reports of drug-induced PRCA, with all drugs and drug regimens. The sudden increase in reports of antibody-mediated PRCA is discussed...
  16. doi request reprint Progress in detecting cell-surface protein receptors: the erythropoietin receptor example
    Steve Elliott
    Department of Hematology Oncology, Amgen Inc, One Amgen Center Drive, Mail Stop 15 2 A, Thousand Oaks, CA, 91320, USA
    Ann Hematol 93:181-92. 2014
    ..Critically analyzing data from tests for cell-surface receptors such as EpoR requires understanding the techniques utilized and demonstrating that results are consistent with current knowledge about receptor biology. ..
  17. pmc The effect of erythropoietin on normal and neoplastic cells
    Steve Elliott
    Oncology Research, Amgen, Thousand Oaks, CA, USA
    Biologics 6:163-89. 2012
    ..Here, we review the biology of endogenous Epo and EpoR expression and function in erythropoiesis, and evaluate the evidence pertaining to the expression of EpoR on normal nonhematopoietic and tumor cells...
  18. ncbi request reprint Comparison of the isoelectric focusing patterns of darbepoetin alfa, recombinant human erythropoietin, and endogenous erythropoietin from human urine
    Don H Catlin
    UCLA Olympic Analytical Laboratory, Department of Molecular and Medical Pharmacology, University of California, Los Angeles, CA 90025, USA
    Clin Chem 48:2057-9. 2002